Transcriptional upregulation of BAG3 upon proteasome inhibition

Biochem Biophys Res Commun. 2008 Jan 11;365(2):381-5. doi: 10.1016/j.bbrc.2007.11.001. Epub 2007 Nov 8.

Abstract

Proteasome inhibitors exhibit antitumoral activity against malignancies of different histology. Emerging evidence indicates that antiapoptotic factors may also accumulate as a consequence of exposure to these drugs, thus it seems plausible that activation of survival signaling cascades might compromise their antitumoral effects. Bcl-2-associated athanogene (BAG) family proteins are characterized by their property of interaction with a variety of partners involved in modulating the proliferation/death balance, including heat shock proteins (HSP), Bcl-2, Raf-1. In this report, we demonstrated that BAG3 is a novel antiapoptotic molecule induced by proteasome inhibitors in various cancer cells at the transcriptional level. Moreover, we demonstrated that BAG3 knockdown by siRNA sensitized cancer cells to MG132-induced apoptosis. Taken together, our results suggest that BAG3 induction might represents as an unwanted molecular consequence of utilizing proteasome inhibitors to combat tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism*
  • Apoptosis Regulatory Proteins / metabolism*
  • Cell Line, Tumor
  • HeLa Cells
  • Humans
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Protease Inhibitors / administration & dosage*
  • Proteasome Endopeptidase Complex / metabolism*
  • Proteasome Inhibitors*
  • Transcription, Genetic / drug effects*
  • Transcriptional Activation / drug effects
  • Up-Regulation

Substances

  • Adaptor Proteins, Signal Transducing
  • Apoptosis Regulatory Proteins
  • BAG3 protein, human
  • Protease Inhibitors
  • Proteasome Inhibitors
  • Proteasome Endopeptidase Complex